which glp 1 agonists have cardiovascular benefit GLP-1 in Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies GLP-1 receptor agonists for cardiovascular

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide a chain of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

found that general control of amino acid synthesis 5 like 1 (GCN5L1) in mitochondria of liver cancer cells can promote the acetylation and inactivation of GLS1 and GLS2 isomers, thus inhibiting mTORC1 activation and cell proliferation

Essentially, the product is heated to a required minimum temperature of 161F for 15 seconds

This process involves the breakdown of fatty acids

Why Glutathione

Sattar N, Lee M, Kristensen SL et al (2021) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials